After video of rat eating ice cream cone in popular outlet at Seawoods station goes viral, Navi Mumbai civic body says it will act if there is a complaint
"So far, we have not received any formal complaint about the viral video of a rat eating an ice cream at a shop in Seawoods," NMMC chief medical health officer Dr Prashant Jawade said on Tuesday. "In case there is any grievance with regards to public health or a rodent-related matter, we can further inquire and take action."
The NMMC spends over Rs 3.5 crore every year to control rodent numbers in all wards to prevent serious diseases.
You Can Also Check:
Mumbai AQI
|
Weather in Mumbai
|
Bank Holidays in Mumbai
|
Public Holidays in Mumbai
"The presence of a rat inside a retail outlet selling food items means that NMMC is unable to control the rodent population," Anarjit Chauhan, an activist, said. "The civic body must suo motu visit that shop shown in the viral video and check how rats are entering these sanitised areas."
Chauhan said all shops pay property tax to the NMMC, part of which is later used for the purpose of public health.
Many citizens reacted after seeing the viral video and said they will avoid eating ice cream or any other snacks from the shops at the station complex.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
SME IPO: Medistep Healthcare's Rs 16-cr public issue to open on Aug 8
Pharmaceutical firm Medistep Healthcare is set to raise a little over Rs 16 crore through its initial public offering ( IPO ), which opens for subscription on August 8. The company's maiden public issue will conclude on August 12. The shares are scheduled to be listed on the NSE SME platform on August 18, Medistep Healthcare said in a statement. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The IPO comprises 37.44 lakh equity shares priced at a fixed Rs 43 per share, aggregating to a total issue size of Rs 16.09 crore. Following the listing, the company is expected to have a market capitalisation of Rs 61.10 crore. The company will utilise the proceeds of the IPO for purchase of plant and machinery for expansion of its existing manufacturing facility, working capital requirements and general corporate purposes. "Proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets," Girdhari Lal Prajapati, Managing Director at Medistep Healthcare, said. Live Events The company is in the business of manufacturing sanitary pads & energy powder, and trading of a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a distribution network. On the financial front, the company recorded revenue from operations of Rs 49.65 crore in FY25, an increase from Rs 39.07 crore in the preceding fiscal. Its profit after tax (PAT) also rose to Rs 4.14 crore in FY25, compared to Rs 3.33 crore in the previous financial year. Fast Track Finsec is the sole lead manager of the public issue while Cameo Corporate Services is the registrar to the issue.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
Time of India
3 hours ago
- Time of India
After video of rat eating ice cream cone in popular outlet at Seawoods station goes viral, Navi Mumbai civic body says it will act if there is a complaint
Navi Mumbai: After a video of a rodent eating an ice cream cone at a popular retail outlet inside the Seawoods station complex went viral, the Navi Mumbai Municipal Corporation (NMMC) said it had not received any complaint about the incident. "So far, we have not received any formal complaint about the viral video of a rat eating an ice cream at a shop in Seawoods," NMMC chief medical health officer Dr Prashant Jawade said on Tuesday. "In case there is any grievance with regards to public health or a rodent-related matter, we can further inquire and take action." The NMMC spends over Rs 3.5 crore every year to control rodent numbers in all wards to prevent serious diseases. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai "The presence of a rat inside a retail outlet selling food items means that NMMC is unable to control the rodent population," Anarjit Chauhan, an activist, said. "The civic body must suo motu visit that shop shown in the viral video and check how rats are entering these sanitised areas." Chauhan said all shops pay property tax to the NMMC, part of which is later used for the purpose of public health. Many citizens reacted after seeing the viral video and said they will avoid eating ice cream or any other snacks from the shops at the station complex.
